Targets › KIR3DL2
1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Apr 2028.
Receptor on natural killer (NK) cells and T cells for MHC class I molecules. Upon binding of peptide-free HLA-F open conformer, negatively regulates NK and T cell effector functions. (UniProt, P43630)
Open in Phaseline: the race on KIR3DL2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| The Lymphoma Academic Research Organisation | Lacutamab anti-KIR3DL2 monoclonal antibody | KIR3DL2 | Phase 2 | Peripheral T Cell Lymphoma | Apr 2028 |
Peripheral T Cell Lymphoma (1)
mixed (1)
The Lymphoma Academic Research Organisation (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.